Managing Myeloma
- 2012-06-18 - FDA staff focus on Onyx cancer drug's side effects-June 20th Advisory Panel Votes- Split Favorable Vote Anticipated by Analysts -- Reuters
- 2012-06-05 - Q&A: SNS01-T is a new approach to treating B-cell cancers that can be modified for all cancers -- BioMedReports
- 2012-06-02 - News Flash: Inhibiting IRE1α-XBP1 pathway impacts survival of myeloma cells-- Medical Net
- 2012-06-01 - Bortezomib-Bendamustine-Prednisone Combination May Be Effective In Newly Diagnosed Myeloma Patients With Kidney Impairment -- The Myeloma Beacon
- 2012-05-18 - NEWS ALERT: Lenalidomide Maintenance for Multiple Myeloma Improves Survival -- Cancer Network-Research Report
- 2012-05-17 - No Bisphosphonate Superior to Another in Multiple Myeloma - Medscape News
- 2012-05-15 - Promising early results from drug combo for advanced multiple myeloma -- Cure Today
- 2012-04-23 - Ratio of involved/uninvolved immunoglobulin quantification by Hevylite assay: Clinical and prognostic impact in Multiple Myeloma.
- 2012-04-23 - Acetylon wins US patent covering composition of matter claims of ACY-1215 - PBR Regulatory Affairs
- 2012-04-23 - International News Alert: Doctor faulted over not telling patient about results - Radio New Zealand
- 2012-04-04 - MMRF launches genomic services to drive success of studying 1000 patients in multiple myeloma study - Pharmabiz.com
- 2012-03-14 - Practice Alert: IMWG consensus on maintenance therapy in multiple myeloma has been published in Blood -- PubMed
- 2012-03-09 - The Top Myeloma Research Of 2011 -- The Myeloma Beacon
- 2012-03-01 - Understanding Prognosis In Multiple Myeloma
- 2012-02-22 - Onyx Pharmaceuticals Completes Enrollment in ASPIRE Phase 3 Carfilzomib Combination Trial for the Potential Treatment of Relapsed Multiple Myeloma -- PR Newswire/Market Watch